Foundation money pulled from China

A major international funder of research and public health efforts on debilitating infectious diseases has frozen hundreds of millions of dollars in grant money to China amidst questions about the country's use of the funds.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

KLAAS HARTMAN / DREAMSTIME.COM

A major international funder of research and public health efforts on debilitating infectious diseases has frozen hundreds of millions of dollars in grant money to China amidst questions about the country's use of the funds. In November, the Global Fund to Fight AIDS, Tuberculosis and Malaria halted payment of $283 million in AIDS grants to China after discovering that the government had breached an agreement by sharing too small a chunk of the money with independent community groups. Then, earlier this month, the Global Fund decided to freeze all funding to the communist nation because an internal investigation turned up evidence of further misuse of the money and fuzzy financial record keeping on local government levels. The Chinese government has until June 7th to respond ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies